Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
Deborah DeRyckere, Alisa B. Lee‐Sherick, Madeline G. Huey, et al.
Clinical Cancer Research (2016) Vol. 23, Iss. 6, pp. 1481-1492
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
K. Myers, Sarah R. Amend, Kenneth J. Pienta
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 334
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Jenna L. Carter, Katie Hege, Jay Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 165
Tumor-associated macrophages: an effective player of the tumor microenvironment
Udit Basak, Tania Sarkar, Sumon Mukherjee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 94
Efferocytosis in the tumor microenvironment
Thomas A. Werfel, Rebecca S. Cook
Seminars in Immunopathology (2018) Vol. 40, Iss. 6, pp. 545-554
Open Access | Times Cited: 116
Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Xuefei Zhou, Xiangrui Liu, Leaf Huang
Advanced Functional Materials (2020) Vol. 31, Iss. 5
Open Access | Times Cited: 114
Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti–PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer
Canan Kasikara, Viralkumar Davra, David Calianese, et al.
Cancer Research (2019) Vol. 79, Iss. 10, pp. 2669-2683
Closed Access | Times Cited: 94
Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
Yumi Yokoyama, Erin D. Lew, Ruth Seelige, et al.
Cancer Research (2019) Vol. 79, Iss. 8, pp. 1996-2008
Open Access | Times Cited: 76
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
Justus M. Huelse, Diana Fridlyand, Shelton Earp, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107577-107577
Open Access | Times Cited: 71
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression
Jinti Lin, Ankai Xu, Jiakang Jin, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 57
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
Alisa B. Lee‐Sherick, Kristen M. Jacobsen, Curtis J. Henry, et al.
JCI Insight (2018) Vol. 3, Iss. 21
Open Access | Times Cited: 67
TAM Receptor Inhibition–Implications for Cancer and the Immune System
Pia Aehnlich, Richard Powell, Marlies J. W. Peeters, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1195-1195
Open Access | Times Cited: 55
Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold
Daniel J. Baillache, Asier Unciti‐Broceta
RSC Medicinal Chemistry (2020) Vol. 11, Iss. 10, pp. 1112-1135
Open Access | Times Cited: 53
MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
Nellie K. McDaniel, Christopher T. Cummings, Mari Iida, et al.
Molecular Cancer Therapeutics (2018) Vol. 17, Iss. 11, pp. 2297-2308
Open Access | Times Cited: 48
MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
Marlies J. W. Peeters, Donata Dulkeviciute, Arianna Draghi, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 9, pp. 1472-1484
Open Access | Times Cited: 47
A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis
Ruiling Chen, Bingyuan Huang, Min Lian, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1478-1490
Closed Access | Times Cited: 16
Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment
Joselyn Cruz Cruz, Kristen C. Allison, Lauren S. Page, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Regulation of brain endothelial cell physiology by the TAM receptor tyrosine kinase Mer
Kaisa E. Happonen, Patrick Burrola, Greg Lemke
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 14
TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting
Marlies J. W. Peeters, Anne Rahbech, Per thor Straten
Cancer Immunology Immunotherapy (2019) Vol. 69, Iss. 2, pp. 237-244
Open Access | Times Cited: 37
LC3-Associated Phagocytosis (LAP): A Potentially Influential Mediator of Efferocytosis-Related Tumor Progression and Aggressiveness
Patrick Fordjour Asare, Eugene Roscioli, P. Hurtado, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 36
Trained innate immunity attenuates macrophage efferocytosis of cancer cells
Alexandros Chatzis, Jakub Lukaszonek, Dimitris Lagos, et al.
(2025)
Open Access
Trained innate immunity attenuates macrophage efferocytosis of cancer cells
Alexandros Chatzis, Jakub Lukaszonek, Dimitris Lagos, et al.
(2025)
Open Access
Targeting the TAM Receptors in Leukemia
Madeline G. Huey, Katherine A. Minson, H. Shelton Earp, et al.
Cancers (2016) Vol. 8, Iss. 11, pp. 101-101
Open Access | Times Cited: 34
Phosphatidylserine receptor-targeting therapies for the treatment of cancer
Miso Park, Keon Wook Kang
Archives of Pharmacal Research (2019) Vol. 42, Iss. 7, pp. 617-628
Closed Access | Times Cited: 32
Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC
P Giroud, Sarah Renaudineau, Laura Gudefin, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 32
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Dan Yan, H. Shelton Earp, Deborah DeRyckere, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5639-5639
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top